Abstract: Objective To analyze the clinical effect of umbilical cord blood transplantation(UCBT)in the treatment of relapsed/refractory acute leukemia(R/R-AL). Methods A retrospective analysis was performed on 22 patients who received UCBT from January 2016 to December 2020 The First People’s Hospital of Chenzhou, including 18 patients with refractory recurrent relapsed/refractory acute myelocytic leukemia (R/R-AML), 4 patients with acute refractory/relapse acute lymphocytic leukemia(R/R-ALL). Results In the study, the rate of +42 d neutrophils implantation was 100% (22/22), the rate of megakaryocyte implantation on +100 days was 90.5%(19/21). The cumulative incidence of Ⅲ-Ⅳ acute graft versus host disease (aGVHD) at + 100 days was 36.4% (8/22), the cumulative incidence of chronic graft versus host disease (cGVHD) for 3 years was 21.1% (4/19), and the cumulative incidence of severe cGVHD at 3 years was 10.5% (2/19). The 3-year cumulative recurrence rate was 3.2%; the 3-year overall survival (OS) was 71.4%; the 3-year disease-free survival (DFS) was 70.9%. Conclusion R/R-AL patients treated with UCBT had low rate of severe cGVHD, low recurrence rate, and higher OS and DFS.

Key words: umbilical cord blood transplantation, acute leukemia, curative effect analysis